Oak Asset Management LLC Sells 646 Shares of Johnson & Johnson (NYSE:JNJ)

Oak Asset Management LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 26,165 shares of the company’s stock after selling 646 shares during the quarter. Johnson & Johnson makes up 1.4% of Oak Asset Management LLC’s holdings, making the stock its 20th largest holding. Oak Asset Management LLC’s holdings in Johnson & Johnson were worth $3,784,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Quad Cities Investment Group LLC increased its stake in Johnson & Johnson by 6.4% during the 4th quarter. Quad Cities Investment Group LLC now owns 2,950 shares of the company’s stock worth $427,000 after purchasing an additional 178 shares in the last quarter. 180 Wealth Advisors LLC increased its stake in Johnson & Johnson by 7.1% during the 4th quarter. 180 Wealth Advisors LLC now owns 14,292 shares of the company’s stock worth $2,067,000 after purchasing an additional 953 shares in the last quarter. Capital CS Group LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $204,000. West Oak Capital LLC increased its stake in Johnson & Johnson by 1.5% during the 4th quarter. West Oak Capital LLC now owns 16,018 shares of the company’s stock worth $2,316,000 after purchasing an additional 230 shares in the last quarter. Finally, Signal Advisors Wealth LLC grew its stake in shares of Johnson & Johnson by 5.6% during the 4th quarter. Signal Advisors Wealth LLC now owns 7,969 shares of the company’s stock worth $1,152,000 after acquiring an additional 420 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

Shares of Johnson & Johnson stock opened at $144.68 on Wednesday. The business has a fifty day simple moving average of $149.12 and a two-hundred day simple moving average of $156.09. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a market capitalization of $348.33 billion, a price-to-earnings ratio of 20.94, a P/E/G ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the firm posted $2.66 EPS. The company’s quarterly revenue was up 5.2% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.43%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 71.78%.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Guggenheim raised their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Royal Bank of Canada raised their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.71.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.